Cardiovascular Research Advance Access originally published online on January 4, 2008
Cardiovascular Research 2008 78(2):257-264; doi:10.1093/cvr/cvm116
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cardiovascular risk factors impair native collateral development and may impair efficacy of therapeutic interventions
1 University Hospital of Wales, Cardiff CF14 4XW, UK
2 University of Chieti, Chieti, Italy
3 Cardiovascular Research Institute, Washington Hospital Center, Washington, DC, USA
* Corresponding author. Tel: +44 29 20744988; fax: +44 29 20745432. E-mail address: tim.kinnaird{at}cardiffandvale.wales.nhs.uk
Animal and early clinical studies of gene therapy for tissue ischaemia suggested that this approach might provide benefit to patients with coronary artery disease not amenable to traditional revascularization. This enthusiasm was then tempered by the subsequent disappointing results of randomized clinical trials and led researchers to develop strategies using progenitor cells as an alternative to improve collateral function. However, the recent publication of several randomized clinical trials reporting either negative or weakly positive results using this approach have led to questions regarding its effectiveness. There are several factors that need to be considered in explaining the discordance between the positive studies of such treatments in animals and the disappointing results seen in randomized patient trials. Aside from the practical issues of arteriogenic therapies, such as effective delivery, vascular remodelling is an extraordinarily complex process, and the administration of a single agent or cell in the hope that it would lead to lasting physiological effects may be far too simplistic an approach. In addition, however, evidence now suggests that many of the traditional cardiovascular risk factors—such as age and hypercholesterolemia—may impair the host response not only to ischaemia but, critically, also to treatment as well. This review discusses the evidence and mechanisms for these observations and highlights future directions that might be taken in an effort to provide more effective therapies.
KEYWORDS Risk factors; Stem cells; Growth factors; Angiogenesis; Collateral vessels; Gene therapy
Time for primary review: 27 days
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J.-S. Silvestre, B. I. Levy, and A. Tedgui Mechanisms of angiogenesis and remodelling of the microvasculature Cardiovasc Res, May 1, 2008; 78(2): 201 - 202. [Full Text] [PDF]
|
|